SEAAIS 2022 77th Annual Meeting
The SEAAIS 2022 meeting is focused on the field of Allergy Asthma and Immunology. It is directed to physicians, physician assistants, nurse practitioners and administrators. The purpose is to engage the audience through oral didactic presentations followed by group discussions. Each presentation is reflective of a need or interest of in-depth conversation or study requested by the membership and/or board. Case presentations are often utilized to solidify the objectives covered in each presentation.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunolgy and Southeastern Allergy, Asthma, & Immunology Society. The American College of Allergy, Asthma & Immunolgy is accredited by the ACCME to provide continuing medical education for physicians.”
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 13 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Allied health professionals
Upon completion of this activity the participant should be able to:
1. Understand the upper and lower airway connection and understand the evidence for use of biologics in asthma.
2. Review the impact of covid on asthma and review the treatment of upper and lower airways in patients with covid.
3. Analyze and evaluate the different treatments for patients with CRSwNP and summarize the new and emerging targeted biologics for CRSwNP.
4. Learn the scope and cause of physician burnout now with covid and be knowledgeable on organization and wellness initiatives for allergists.
5. Discuss and learn the proper diagnostic evaluation of chronic cough an understand the term refractory chronic cough and current treatment options.
6. Examine the current literature dealing with vaccine hesitancy and Covid-19 vaccines and provide a classification of adverse reactions related to Covid-19 vaccines.
7. Define the general clinical characteristics of long Covid and provide a proposed mechanistic model of pathogenesis of the syndrome.
8. Understand and discuss payment challenges for allergy codes by MCOs and understand in-office implementation of USP 797.
9. Discuss limitations of routine diagnostic testing in chronic urticaria and discuss management options for refractory chronic urticaria.
10. Analyze and evaluate the different treatments for patients with atopic dermatitis and summarize the new and emerging targeted biologics for atopic dermatitis.
11. Define different types of mast cell activation disorders and discuss workup and diagnostic criteria for each.
12. Evaluate different diagnostic modalities for food allergy and recognize novel therapeutic strategies for IgE-mediated food allergy.
13. Recognize updates in recent guidelines for anaphylaxis and develop a diagnostic algorithm for patients presenting with idiopathic anaphylaxis.
14. To review the mechanisms of selling in HAE and provide an update on treatment options.
15. Understand the landscape of medical practice, discuss how to value a practice and explain options for practice ownership/partnership.
16. Gain an understanding of the laboratory assessment of CVID and discuss the non-infectious complications of CVID.
17. Define low T2 Asthma and review the pathophysiology underlying different types of low T2 Asthma.
Disclosure Policy and Disclosures
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewer, and other individuals in a position to control or influence the content of an activity must disclose ALL financial relationships with any ineligible company. The ACCME defines an “ineligible company” (formerly commercial interest) as a company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. (Examples of ineligible companies include: Advertising, marketing, or communication firms whose clients are ineligible companies; bio-medical startups that have begun a governmental regulatory approval process; compounding pharmacies that manufacture proprietary compounds; device manufacturers or distributors; diagnostic labs that sell proprietary products; growers, distributors, manufacturers or sellers of medical foods and dietary supplements; manufacturers of health-related wearable products; pharmaceutical companies or distributors; pharmacy benefit managers; reagent manufacturers or sellers). For more information, visit www.accme.org.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.
All identified conflicts of interest have been mitigated.
Michael Blaiss, MD, Speaker: Consultant: Sanofi, Regeneron, AZ, Amgen, Merck, Pfizer, Perrigo, Covis, ALK, TerSera, Lanier Biotherapeutics
Peter Dicpinigaitis, MD, Speaker: Consultant: Bayer, Bellus, Chiesi, Merck, Regeneron, Shionogi;
Weily Soong, MD, Speaker: Research Investigator: Allakos, AstraZeneca, Lilly, Novartis, Genentech, Regeneron, and Sanofi; Consultant or Speaker: AstraZeneca, GSK, Genentech, Novartis, Regeneron, and Sanofi.
Anju Peters, MD, Speaker: Research: Optinose, Sanofi Regeneron; Consulting: AstraZeneca, GSK, Optinose, Sanofi Regeneron
Matthew Giannetti, MD, Speaker: Research: Blueprint Medicines, Cogent Biosciences; Consulting: Cogent Biosciences
Jay Lieberman, MD, Speaker: Research/Advisor: DBV Technologies, Aimmune Therapeutics, Regneron, Alk-Abello, Novartis
Marc Riedl, MD, Speaker: Research: Biocryst, Biomarin, CSL Behring, Ionis, Kalvista, Pharvaris, Takeda; Speaker: CSL Behring, Pharming, Takeda; Consulting: Astria, Biocryst, Biomarin, CSL Behring, Cycle Pharma, Fresenius-Kabi, Ipsen, Kalvista, Ono Pharma, Pfizer, Pharming, Pharvaris, RegenexBio, Sanofi-Regeneron, Shire/Takeda
Tara Carr, MD, Speaker: Consulting/Advisor: AstraZeneca, Genentech, Roche; Royalties: Editorial compensation and royalties from UpToDate
The following have no relevant financial relationships to disclose:
Joseph Bellanti, MD
James Sublett, MD
Stanley Fineman, MD
- 13.00 AMA PRA Category 1 Credit™
- 13.00 Attendance